AbbVie Reports Data from the P-III Trial of Atogepant as a Preventive Treatment of Migraine
Shots:
- AbbVie has reported interim results from the 156wks. P-III (Study 3101-312-002) extension trial assessing the long-term safety & tolerability of atogepant (60mg, oral) as a preventive treatment of migraine in patients (n=595) with chronic or episodic migraine
- The trial involved patients from the P-III (PROGRESS & ELEVATE) studies who concluded the evaluations and had a baseline monthly migraine day burden of 14.5 days
- The results demonstrated an improvement in monthly migraine days by an average of 8.5 days and a ≥50% reduction in monthly migraine days was observed in 70% of patients at wks.13-16, both of which sustained for over 48wks.
Ref: AbbVie | Image: AbbVie
Related News:- AbbVie Receives the MHRA’s Marketing Authorisation of Aquipta (atogepant) for the Prevention of Migraines in Adults
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.
